Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
A candidate inactivated poliovirus vaccine derived from live-attenuated Sabin strains (sIPV), which are used in the oral poliovirus vaccine (OPV), was prepared in a large-production scale. The modification of viral antigenic epitopes during the formalin inactivation process was investigated by capture ELISA assays using type-specific and antigenic site-specific monoclonal antibodies (MoAbs). The major antigenic site 1 was modified during the formalin inactivation of Sabin 1. Antigenic sites 1-3 were slightly modified during the formalin inactivation of Sabin 2 strain. Sites 1 and 3 were altered on inactivated Sabin 3 virus. These alterations were different to those shown by wild-type Saukett strain, used in conventional IPV (cIPV). It has been previously reported that type 1 sIPV showed higher immunogenicity to type 1 cIPV whereas types 2 and 3 sIPV induced lower level of immunogenicity than their cIPV counterparts. Our results suggest that the differences in epitope structure after formalin inactivation may account, at least in part, for the observed differences in immunogenicity between Sabin and wild-type inactivated poliovaccines.
Tano
Yoshio
Y
Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama-shi, Tokyo 208-0011, Japan; Japan Poliomyelitis Research Institute, Kumegawa-cho 5-34-4, Higashimurayama-shi, Tokyo 189-0003, Japan.
Shimizu
Hiroyuki
H
Martin
Javier
J
Nishimura
Yorihiro
Y
Simizu
Bunsiti
B
Miyamura
Tatsuo
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000914:Antibodies, Viral / Q000378:metabolism*; D000956:Antigens, Viral / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology*; D005557:Formaldehyde / Q000276:immunology; D051379:Mice; D009500:Neutralization Tests; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*